Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: The LIBER trial

Familial Cancer

Volumn 11, Issue 1, 2012, Pages 77-84

  Pujol, Pascal ^a,b   Lasset, Christine ^c   Berthet, Pascaline ^d   Dugast, Catherine ^e   Delaloge, Suzette ^f   Fricker, Jean Pierre ^g   Tennevet, Isabelle ^h   Chabbert Buffet, Nathalie ⁱ   This, Pascale ^j   Baudry, Karen ^a   Lemonnier, Jerome ^k   Roca, Lise ^b   Mijonnet, Sylvie ^k   Gesta, Paul ^l   Chiesa, Jean ^m   Dreyfus, Helene ⁿ   Vennin, Philippe ^o   Delnatte, Capucine ^p   Bignon, Yves Jean ^q   Lortholary, Alain ^r   Prieur, Fabienne ^s   Gladieff, Laurence ^t   Lesur, Anne ^u   Clough, Krishna B ^v   Nogues, Catherine ^j   Martin, Anne Laure ^k   more..

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b CENTRE VAL D AURELLE   (France)

^c UNIVERSITÉ LYON 1   (France)

^d CENTRE FRANÇOIS BACLESSE   (France)

^e CENTRE EUGÈNE MARQUIS   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g CENTRE PAUL STRAUSS   (France)

^h CENTRE HENRI BECQUEREL   (France)

ⁱ HÔPITAL TENON   (France)

^j INSTITUT CURIE   (France)

^k UNICANCER   (France)

^l Centre Hospitalier de Niort   (France)

^m NÎMES UNIVERSITY HOSPITAL   (France)

ⁿ INSTITUT SAINTE CATHERINE   (France)

^o CENTRE OSCAR LAMBRET   (France)

^p Centre Gauducheau   (France)

^q CENTRE JEAN PERRIN   (France)

^r Clinique Catherine de Sienne   (France)

^s UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^t INSTITUT CLAUDIUS REGAUD   (France)

^u CENTRE ALEXIS VAUTRIN   (France)

^v Institut du Sein   (France)

more..

Author keywords

BRCA1; BRCA2; Breast cancer; Chemoprevention; Letrozole; Uptake

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; LETROZOLE; PLACEBO;

ADULT; ARTICLE; BREAST CANCER; CANCER PREVENTION; CHEMOPROPHYLAXIS; COHORT ANALYSIS; FEMALE; GENE MUTATION; GERMLINE MUTATION; HEALTH SURVEY; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MEDICAL RECORD REVIEW; OVARIECTOMY; PATIENT ATTITUDE; PATIENT PARTICIPATION; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICIAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT REFUSAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; MIDDLE AGED; MUTATION; NITRILES; OVARIECTOMY; POSTMENOPAUSE; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TRIAZOLES;

EID: 84858277600     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-011-9484-4     Document Type: Article

References (41)

1. Antoniou A et al (2003) Average risks of breast and ovarian cancer associated with BRCA1/2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117-1130 (Pubitemid 36530000)
2. Robson M, Offit K (2007) Clinical practice. Management of an inherited predisposition to breast cancer. N Engl J Med 357(2): 154-162 (Pubitemid 47057733)
3. King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645):643-646 (Pubitemid 37310920)
4. Rebbeck TR et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol 22(6):1055-1062 (Pubitemid 41095038)
5. Klijn JEA (2004) Results of the extended series on prophylactic mastectomy versus surveillance in BRCA1/2 mutation carriers in Rotterdam. Breast Cancer Res Treat 88(Suppl 1):10
6. Meijers-Heijboer H et al (2001) Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1/2 mutation. N Engl J Med 345(3):159-164 (Pubitemid 32662123)
7. Metcalfe KA, Semple JL, Narod SA (2005) Time to reconsider subcutaneous mastectomy for breast-cancer prevention. Lancet Oncol 6(6):431-434 (Pubitemid 40753749)
8. Gahm J, Wickman M, Brandberg Y (2010) Bilateral prophylactic mastectomy in women with inherited risk of breast cancer: prevalence of pain and discomfort, impact on sexuality, quality of life and feelings of regret 2 years after surgery. Breast 19(6): 462-469
9. Brandberg Y et al (2008) Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study. J Clin Oncol 26(24):3943-3949
10. Metcalfe KA et al (2008) International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 122(9):2017-2022 (Pubitemid 351441190)
11. Habermann EB et al (2010) Are mastectomy rates really increasing in the United States? J Clin Oncol 28(21):3437-3441
12. Tuttle TM et al (2010) The increasing use of prophylactic mastectomy in the prevention of breast cancer. Curr Oncol Rep 12(1): 16-21
13. McLaughlin CC, Lillquist PP, Edge SB (2005) Surveillance of prophylactic mastectomy: trends in use from 1995 to 2005. Cancer 115(23):5404-5412
14. Wood WC (2009) Should the use of contralateral prophylactic mastectomy be increasing as it is? Breast 18(Suppl 3):S93-S95
15. King MC et al (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: national surgical adjuvant breast and bowel project (NSABP-P1) breast cancer prevention trial. JAMA 286(18):2251-2256
16. Metcalfe KA (2009) Oophorectomy for breast cancer prevention in women with BRCA1/2 mutations. Womens Health (Lond Engl) 5(1):63-68
17. Domchek SM, Rebbeck TR (2007) Prophylactic oophorectomy in women at increased cancer risk. Curr Opin Obstet Gynecol 19(1):27-30 (Pubitemid 46095869)
18. Kauff ND, Barakat RR (2007) Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1/2. J Clin Oncol 25(20):2921-2927 (Pubitemid 47123156)
19. Noruzinia M, Coupier I, Pujol P (2005) Is BRCA1/2-related breast carcinogenesis estrogen dependent? Cancer 104(8):1567-1574 (Pubitemid 41437418)
20. Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers. J Natl Cancer Inst 101(2):80-87
21. Jones LP et al (2008) Activation of estrogen signaling pathways collaborates with loss of BRCA1 to promote development of ER alpha-negative and ER alpha-positive mammary preneoplasia and cancer. Oncogene 27(6):794-802 (Pubitemid 351186312)
22. Fisher B et al (2005) Tamoxifen for the prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 97(22): 1652-1662 (Pubitemid 41672231)
23. Powles TJ et al (2007) Twenty-year follow-up of the royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 9(4):283-290 (Pubitemid 47073491)
24. Cummings SR et al (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA 281(23):2189-2197 (Pubitemid 29275701)
25. Vogel VG et al (2010) Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res (Phila) 3(6):696-706
26. Cuzick J et al (2007) Long-term results of tamoxifen prophylaxis for breast cancer: 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99(4):272-282 (Pubitemid 47073490)
27. Jordan VC (2007) Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat Rev Cancer 7(1): 46-53
28. Veronesi U et al (2007) Tamoxifen for the prevention of breast cancer: late results of the Italian randomized tamoxifen prevention trial among women with hysterectomy. J Natl Cancer Inst 99(9):727-737 (Pubitemid 47073533)
29. Ropka ME, Keim J, Philbrick JT (2010) Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol 28:3090-3095
30. Waters WA, Cronin KA, Graubard BI, Han PK, Freedman AN (2010) Prevalence of tamoxifen use for breast cancer chemo-prevention among US women. Cancer Epidemiol Biomarkers Prev 19:443-446
31. Dowsett M et al (2010) Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28(3):509-518
32. Goss PE et al (2007) National cancer institute of Canada clinical trials group MAP.3 trial: evaluation of exemestane to prevent breast cancer in postmenopausal women. Clin Breast Cancer 7(11):895-900
33. Cuzick J (2008) IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. Expert Rev Anticancer Ther 8(9):1377-1385
34. Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H, NCIC CTG MAP.3 Study Investigators (2011) Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364(25):2381-2391
35. Lecarpentier J, Noguès C, Mouret-Fourme E, Stoppa-Lyonnet D, Lasset C, Caron O, Fricker JP, Gladieff L, Faivre L, Sobol H, Gesta P, Frenay M, Luporsi E, Coupier I (2011) Variation in breast cancer risk with mutation position, smoking, alcohol, and chest X-ray history, in the French national BRCA1/2 carrier cohort (GENEPSO). GENEPSO, Lidereau R, Andrieu N. Breast Cancer Res Treat. 2011 Jul 15 (epub ahead of print)
36. Cuzick J et al (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361(9354):296-300 (Pubitemid 36126189)
37. Evans D et al (2001) Uptake of screening and prevention in women at very high risk of breast cancer. Lancet 358(9285): 889-890 (Pubitemid 32900574)
38. Evans DG, Harvie M, Bundred N, Howell A (2010) Uptake of breast cancer prevention and screening trials. J Med Genet 47(12):853-855. Epub 2010 Oct 23
39. Graeser MK et al (2009) Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 27(35): 5887-5892
40. Geisler J, Lonning PE (2010) Impact of aromatase inhibitors on bone health in breast cancer patients. J Steroid Biochem Mol Biol 118(4-5):294-299
41. Mortimer JE (2010) Managing the toxicities of the AI. Curr Opin Obstet Gynecol 22(1):56-60